Ten stocks kicked off the trading week boasting high gains, defying a pessimistic market sentiment, as investors took heart from a flurry of fresh company-specific catalysts that boosted buying appetite.
Of the 10, six hit new record highs, while seven belong to the biopharmaceutical industry.
In this article, we spotlight the names that led the charge on Monday and break down the reasons behind their gains.
To come up with the list, we focused exclusively on stocks with a $2 billion market capitalization and 5 million shares in trading volume.
Photo by Tima Miroshnichenko on Pexels
10. Dyne Therapeutics, Inc. (NASDAQ:DYN)
Dyne Therapeutics jumped by 9.47 percent on Monday to finish at $22.20 apiece as investors cheered the encouraging results from its ongoing clinical trial to test the efficacy of therapy candidate, zeleciment rostudirsen, for individuals with Duchenne muscular dystrophy (DMD).
In an update on the same day, Dyne Therapeutics, Inc. (NASDAQ:DYN) said that the drug candidate met its primary endpoint, demonstrating a 5.46 percent increase in muscle-content adjusted dystrophin levels alongside functional improvements across multiple clinical endpoints.
“With its high level of dystrophin expression, favorable safety profile, convenient monthly dosing regimen, and functional improvement as assessed by six prespecified clinical measures, z-rostudirsen has the potential to transform the care of those living with DMD amenable to exon 51 skipping,” said Dyne Therapeutics, Inc. (NASDAQ:DYN) President and CEO John Cox.
Notably, the therapy was considered generally safe and tolerable, with the commonly reported adverse effects being only fever and headache.
The trial enrolled 32 ambulant and non-ambulant males with DMD aged 4 to 16 and had mutations amenable to a method called exon 51 skipping.
The company said it is on track to submit an accelerated approval in the second quarter of 2026, positioning itself to launch the said therapy in the first quarter of 2026.
9. Carvana Co. (NYSE:CVNA)
Carvana soared to a new all-time high on Monday after 10 consecutive days of rally, as investors took heart from its official inclusion in the S&P 500 index.
At intra-day trading, Carvana Co. (NYSE:CVNA) jumped to its highest price of $456.97 before paring gains to end the day just up by 12.06 percent at $447.98 apiece.
This followed the S&P Dow Jones Indices’ report on Friday, adding Carvana Co. (NYSE:CVNA) to the S&P 500 recomposition alongside building materials firm CRH PLC and construction services firm Comfort Systems USA, effective December 22, 2025.
Its inclusion was a significant milestone, having been written off as a “zombie” by Wall Street a few years back.
Share prices of companies added to benchmark indices typically pop as fund managers would need to reposition their portfolios to mirror the composition ahead of the start of their inclusion.
Additionally, the S&P Dow Jones Indices also announced changes to the composition of the S&P MidCap 400 and the S&P SmallCap 600, effective on the same date.
Carvana Co.’s (NYSE:CVNA) rally was supported by the increasing hopes for an interest rate cut, which is set to benefit the company through lower car loans for buyers.
Policymakers are expected to announce on Wednesday, December 10, their decision on interest rates, and economists are highly expecting a 25-basis point rate cut.
Hedge Fund Resource Center